News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,759 Results
Type
Article (323)
Press Release (1436)
Section
Business (773)
Career Advice (8)
Deals (82)
Drug Delivery (4)
Drug Development (124)
FDA (83)
Job Trends (39)
News (1174)
Policy (246)
Tag
Academia (1)
Alliances (119)
Alzheimer's disease (3)
Approvals (84)
Autoimmune disease (1)
Bankruptcy (1)
Best Places to Work (15)
Biosimilars (43)
Breast cancer (2)
Cancer (7)
Cardiovascular disease (4)
Career advice (8)
Clinical research (99)
Collaboration (5)
COVID-19 (12)
C-suite (1)
Data (1)
Diabetes (1)
Diagnostics (3)
Drug pricing (7)
Earnings (195)
Events (86)
Executive appointments (3)
FDA (93)
GLP-1 (7)
Government (43)
Guidances (4)
Healthcare (45)
Immunology and inflammation (5)
Infectious disease (13)
Interviews (2)
IPO (24)
IRA (1)
Job creations (24)
Job search strategy (8)
Layoffs (20)
Legal (132)
Lung cancer (1)
Lymphoma (1)
Medical device (7)
Medtech (7)
Mergers & acquisitions (57)
Metabolic disorders (4)
Multiple sclerosis (1)
Neuroscience (4)
NextGen: Class of 2025 (9)
Non-profit (3)
Obesity (3)
Opinion (6)
Patents (3)
People (423)
Pharmacy benefit managers (3)
Phase I (17)
Phase II (31)
Phase III (64)
Pipeline (10)
Policy (2)
Postmarket research (8)
Preclinical (4)
Real estate (17)
Regulatory (90)
Research institute (2)
Resumes & cover letters (1)
Startups (9)
The Weekly (1)
Vaccines (2)
Weight loss (3)
Date
Last 7 days (2)
Last 30 days (7)
Last 365 days (96)
2025 (32)
2024 (104)
2023 (65)
2022 (155)
2021 (117)
2020 (144)
2019 (136)
2018 (114)
2017 (106)
2016 (113)
2015 (174)
2014 (107)
2013 (50)
2012 (57)
2011 (52)
2010 (42)
Location
Africa (9)
Asia (128)
Australia (21)
California (9)
Canada (1)
China (11)
Connecticut (1)
Europe (496)
Illinois (2)
India (1)
Kansas (1)
Maryland (2)
Massachusetts (3)
Minnesota (2)
Missouri (1)
Nevada (1)
New Jersey (9)
New York (3)
North Carolina (3)
Northern California (8)
Pennsylvania (1)
South America (10)
Southern California (1)
United States (35)
Washington State (1)
1,759 Results for "sandoz".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
April 29, 2025
·
5 min read
Press Releases
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
April 30, 2025
·
9 min read
Legal
Regeneron Sues Sandoz in Federal Court to Block Eylea Biosimilar
In its legal complaint, filed in the District Court for New Jersey, Regeneron alleges that Sandoz failed to provide it with relevant information required under the Biologics Price Competition and Innovation Act.
August 29, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Sandoz reports strong FY 2024 results and Q4 2024 sales
March 5, 2025
·
21 min read
Drug Delivery
Sandoz’s Biosimilar Skyrockets After CVS Removes AbbVie’s Humira from Formularies
Prescriptions for Sandoz’s Hyrimoz, a biosimilar version of AbbVie’s Humira, have shot up after CVS Caremark took the blockbuster arthritis treatment off its major national commercial formularies on April 1.
April 16, 2024
·
2 min read
·
Tristan Manalac
Business
Sandoz reports first quarter 2024 sales
Sandoz, the global leader in generic and biosimilar medicines, announced net sales for the first quarter 2024.
May 7, 2024
·
12 min read
Press Releases
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
February 24, 2025
·
13 min read
FDA
Sandoz Nabs FDA Approvals for First Two Biosimilars for Amgen’s Denosumab
Sandoz’s two interchangeable biosimilars, Jubbonti and Xgeva, are poised to challenge Amgen’s blockbuster bone drug denosumab. However, no launch details were announced Tuesday due to ongoing patent litigation.
March 6, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
January 14, 2025
·
7 min read
Policy
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
Sandoz, the global leader in generic and biosimilar medicines, announced that the European Commission has granted marketing authorization for Wyost®1 and Jubbonti®2, the first and only biosimilar versions of reference medicines Xgeva®*3 and Prolia®*4 in Europe.
May 22, 2024
·
6 min read
1 of 176
Next
